Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection

Amelia K. Pinto  
*Washington University School of Medicine in St. Louis*

James D. Brien  
*Washington University School of Medicine in St. Louis*

Chia-Ying Kao Lam  
*MacroGenics, Inc.*

Syd Johnson  
*MacroGenics, Inc.*

Cindy Chiang  
*Pasteur Institute of Rome*

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Pinto, Amelia K.; Brien, James D.; Lam, Chia-Ying Kao; Johnson, Syd; Chiang, Cindy; Hiscott, John; Sarathy, Vanessa V.; Barrett, Alan D.; Shresta, Sujan; and Diamond, Michael S., "Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection." mBio. 6, 5. e01316-15. (2015).  
https://digitalcommons.wustl.edu/open_access_pubs/4213

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Amelia K. Pinto, James D. Brien, Chia-Ying Kao Lam, Syd Johnson, Cindy Chiang, John Hiscott, Vanessa V. Sarathy, Alan D. Barrett, Sujan Shresta, and Michael S. Diamond
Dengue virus (DENV) is a mosquito-transmitted, enveloped, positive-sense RNA virus and member of the flavivirus genus of the Flaviviridae family, which includes several other viruses (e.g., West Nile virus [WNV], Japanese encephalitis virus [JEV], and yellow fever virus [YFV]) that cause disease globally. Infection by any of four serologically distinct viruses (DENV serotype 1 [DENV-1], DENV-2, DENV-3, and DENV-4) causes dengue fever (DF), an acute self-limiting febrile illness, or severe dengue, which manifests as a potentially fatal hemorrhagic fever and vascular leakage syndrome. Epidemiological studies suggest that two populations are at highest risk for severe dengue infection: infants born to dengue-immune mothers who are infected for the first time (infant dengue hemorrhagic fever) and children or adults who experience a second infection with a different DENV serotype (1–3).

DENV has a 10.7-kb, positive-sense RNA genome with 5’ and 3’ untranslated regions flanking a polyprotein that encodes three structural (C, prM/M, and E) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins. The E protein is comprised of three domains, I (E-DI), II (E-DII), and III (E-
DIIL, with E-DII and E-DIII containing the fusion peptide and putative viral receptor binding site(s), respectively (reviewed in references 4 and 5). Among the structural proteins, prM and E are the primary antigenic targets of the humoral immune response (6–9). The most potently neutralizing antibodies target sites on the lateral ridge and A strand of E-DIII (10–16), quaternary epitopes on adjacent E proteins near the E-DII hinge region (17–20), amino acids near the bc loop of E-DII (21), and a conserved epitope at the E dimer interface (22).

One hypothesis as to why certain individuals are more vulnerable to severe DENV infection is that preexisting, poorly neutralizing antibodies acquired passively (infants) or after primary infection (children and adults) facilitate virus entry into Fcy receptor (FcγR)-bearing target cells, thereby increasing viral replication, cytokine levels, inflammation, and ultimately, disease severity (reviewed in reference 23). Experimental evidence in mice supports this idea. Initial studies showed that passive transfer of subneutralizing concentrations of monoclonal antibody (MAb) or polyclonal antibody (PAb) enhanced infection and disease caused by DENV-2 in 129/Sv mice deficient in both alpha/beta interferon (IFN-α/β) receptor (Ifnar) and IFN-γ receptor (Ifngr) (known as AG129) (24–26). Subsequent reports extended these findings to other DENV serotypes in AG129 mice (DENV-1 [19], DENV-3 [27], and DENV-4 [13, 28, 29]) or Ifnar−/− C57BL/6 mice. Ifnar−/− mice in either the 129/Sv or C57BL/6 background develop a severe DENV-like disease when infected with very high DENV-2 doses or in the presence of enhancing anti-DENV antibodies (25, 30–33).

The utility of these highly immunocompromised mice to provide a mechanistic understanding of DENV pathogenesis and disease remains controversial. The use of laboratory or mouse-adapted DENV-2 strains has been required to induce mortality or neuroinvasive disease (34), and the latter is not commonly observed in DENV-infected humans. Studies with DENV-2 indicate that mice with deficiencies in innate immunity are needed to study DENV pathogenesis because the viral NS3 and NS5 proteins induce degradation of human but not mouse STING and STAT2, respectively (35–38); STING and STAT2 are key components of the IFN induction and signaling pathway. Thus, DENV generally does not replicate to high titers or cause clinical signs of disease in wild-type (WT) mice, in part because DENV nonstructural proteins fail to antagonize host innate immune responses efficiently. We recently demonstrated that WN V infection of the more immunocompetent LysM Cre+ Ifnarlox/lox (denoted as IfnarBT herein) or CD11c Cre+ IfnarBT mice, which lack Ifnar expression only on subsets of myeloid cells, resulted in a-sepsis-like syndrome that shared features of DENV disease in humans (39). Another group recently used the LysM Cre+ IfnarBT and CD11c Cre+ IfnarBT mice to generate a model of DENV-2 infection and study adaptive immunity after immunization with a candidate vaccine (40). Here, we administered enhancing amounts of anti-E and anti-prM MAb to LysM Cre+ IfnarBT mice prior to infection with either DENV-2 or DENV-3 and generated an antibody-dependent enhancement (ADE) of infection model of disease that shared many characteristics of severe dengue in humans. We used this model to establish the therapeutic efficacy of an antibody-based bispecific dual-affinity retargeting molecule (DART) that targets epitopes on the A strand of E-DIII and the fusion loop in E-DII and a novel sequence-optimized RIG-1 receptor agonist that stimulates antiviral innate immunity. These studies provide the first demonstration of severe ADE-mediated DENV infection in LysM Cre+ IfnarBT mice and illustrate the utility of this model to evaluate antibody- and innate immune-based antiviral therapies to limit DENV pathogenesis.

RESULTS

Dengue virus infection in LysM Cre+ IfnarBT mice. Prior analysis established that myeloid cells are targets for human DENV infection in vivo (41). The relevance of Ifnar−/− mice in studying DENV pathogenesis has been questioned because of the central role of IFN signaling in priming innate and adaptive immune responses (42–44). In an attempt to study DENV pathogenesis in a more immunocompetent animal, we used LysM Cre+ IfnarBT mice that conditionally delete Ifnar only in subsets of myeloid cells. In splenocytes, flow cytometric analysis revealed substantially reduced Ifnar expression on the surface of CD11b+CD11c+ macrophages from LysM Cre+ IfnarBT mice compared to the results for WT mice. In contrast, the levels of Ifnar expression on B220+ B cells, CD3+ T cells, CD11b+CD11c− monocytes, and CD11b+CD11c− dendritic cells from LysM Cre+ IfnarBT mice were comparable to the levels seen in WT mice (Fig. 1A).

Initially, we compared morbidity in DENV-infected WT, LysM Cre+ IfnarBT and Ifnar−/− mice. Four-week-old mice lacking Ifnar expression on all cells or only on myeloid cell subsets rapidly developed disease within days of DENV-2 (strain D2S20, 1 × 106 focus-forming units [FFU]) or DENV-3 (strain C0369/94, 1 × 106 FFU) infection, as reflected by the development of weight loss (Fig. 1B and C) ruffled fur, and hunched appearance (data not shown). In comparison, and as expected, WT mice infected with DENV-2 or DENV-3 did not develop signs of disease.

To define the basis for the DENV-induced disease in LysM Cre+ IfnarBT mice, we assessed viral burdens. WT, LysM Cre+ IfnarBT, and Ifnar−/− mice were inoculated intravenously with 1 × 106 FFU of DENV-2 (strain D2S20) or 1 × 107 FFU of DENV-3, and the levels of viral RNA in the serum, kidney, spleen, and liver were determined at 4 days after infection using quantitative reverse transcription-PCR (qRT-PCR). DENV-2 or DENV-3 replication was markedly enhanced (Fig. 1D to G) in LysM Cre+ IfnarBT mice compared to the levels of replication in WT mice. These values approached but did not attain those observed in Ifnar−/− mice, which lack Ifnar signaling in all cell types.

Antibody-enhanced DENV disease in LysM Cre+ IfnarBT mice. Given that LysM Cre+ IfnarBT mice sustained infection and disease after DENV inoculation, we evaluated whether more severe disease would be observed if enhancing and cross-reactive anti-prM (2H2) and anti-E (4G2) MAb were administered. Indeed, more severe disease was observed in LysM Cre+ IfnarBT mice that were treated with enhancing MAbS than in those treated with an isotype control anti-Chikungunya virus MAb (CHK-152) (45) prior to infection with 1 × 106 FFU of DENV-2 (Fig. 2A). However, no mortality was seen with the 1 × 106 FFU dose of DENV-2, even in the presence of enhancing MAbS (data not shown). With a higher dose of DENV-2 (1 × 107 FFU), we did observe increased mortality under ADE conditions (55 versus 8 percent mortality; P < 0.006) (Fig. 2B). As DENV infection in humans is predominantly a disease that does not cause lethality, we performed subsequent experiments using the lower 1 × 106 FFU dose of DENV-2.

To define the relevance of the LysM Cre+ IfnarBT mouse model of DENV-2 infection, we assessed the impact of ADE on labora-
Hemoconcentration (shown by elevated hematocrit [HCT]), which reflects changes in vascular permeability, was observed in DENV-infected LysM Cre<sup>+</sup> Ifnar<sup>−/−</sup> mice, and this phenotype was exacerbated in the presence of enhancing antibodies (HCT was 42 ± 2 for no virus, 46 ± 4 for DENV-2 alone, and 51 ± 5 for DENV-2 plus anti-prM and anti-E MAbs) (Fig. 2C). Thrombocytopenia (low platelet [PLT] counts) was also detected in...
DENV-infected LysM Cre⁺ Ifnar⁶/⁶ mice, although ADE did not alter its magnitude (PLT count was 300 ± 85 for no virus, 108 ± 59 for DENV-2 alone, and 155 ± 67 for DENV-2 plus anti-prM and anti-E MAbs) (Fig. 2D). An elevated blood urea nitrogen (BUN) level, which reflects renal damage, was measured only in DENV-infected LysM Cre⁺ Ifnar⁶/⁶ mice treated with enhancing antibodies (BUN was 15 ± 4 for no virus, 16 ± 4 for DENV-2 alone, and 68 ± 21 for DENV-2 plus anti-prM and anti-E MAbs) (Fig. 2E). Liver injury, as manifested by elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels in serum, was also observed in DENV-infected LysM Cre⁺ Ifnar⁶/⁶ mice, with greater damage present under conditions of ADE (AST and ALT were 156 ± 49 and 82 ± 36, respectively, for no virus, 300 ± 208 and 125 ± 53 for DENV-2 alone, and 503 ± 223 and 258 ± 149 for DENV-2 plus anti-prM and anti-E MAbs) (Fig. 2F and G). Overall, enhancing antibodies in the context of DENV infection of LysM Cre⁺ Ifnar⁶/⁶ mice worsened many of the laboratory parameters that are seen during cases of severe DENV in humans (46). In comparison, in Ifnar⁻/⁻ mice, the administration of enhancing antibodies resulted in an increased hematocrit (44 ± 3 for DENV-2 alone and 53 ± 9 for DENV-2 plus anti-prM and anti-E MAbs) but did not alter AST or ALT levels or platelet counts beyond that seen with virus alone (data not shown).

To determine the basis for the exacerbated clinical disease in LysM Cre⁺ Ifnar⁶/⁶ mice, we assessed the effects of enhancing antibodies on the DENV-2 viral burden. At day 4 after infection, we observed higher levels of DENV RNA in the sera of infected LysM Cre⁺ Ifnar⁶/⁶ than in the sera of WT mice, with further increases when animals were pretreated with enhancing MAbs (Fig. 3A). Analogous results were observed in other tissues after DENV infection and antibody treatment, including the kidney, spleen, and liver (Fig. 3B to D).

We evaluated cytokine levels in serum and vascular leakage in tissues, which are two features of severe DENV infection in humans (23, 47). Elevated levels of interleukin 1β (IL-1β) and IL-12 were observed in LysM Cre⁺ Ifnar⁶/⁶ mice compared to the levels in
WT mice after DENV-2 infection (Fig. 3E and F). Moreover, in the setting of ADE, the levels of several other proinflammatory cytokines were substantially higher in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice than they were in the setting of DENV infection alone (Fig. 3G and H; Table 1). Since previous studies in DENV-infected AG129 mice demonstrated increased vascular permeability in the liver (24, 25, 27), as measured by extravasation of Evans blue dye, we performed similar studies in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice (Fig. 3I to L).

Leakage of Evans blue dye into the kidney and liver was observed at day 4 after DENV infection in the context of ADE in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice, which parallels the enhanced capillary permeability seen during severe DENV disease in humans (48). However, the increased dye extravasation was tissue restricted and was not observed in the spleen or small intestine of these mice.

To corroborate these findings, we performed analogous experiments with enhancing MAbs in DENV-3-infected LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice using a non-mouse-adapted DENV-3 human isolate (strain C0360/94) (27). Although lethal infection was not observed in this model at a dose of 1 x 10<sup>7</sup> FFU, some mortality (~33%) was seen at a dose of 3 x 10<sup>7</sup> FFU in A129 mice (data not shown). More severe DENV-3-induced disease occurred in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> but not WT mice when enhancing amounts of anti-E MAb were present, as determined by greater weight loss (Fig. 4A; also data not shown). The addition of the anti-prM MAb to the anti-E MAb did not worsen clinical disease further after DENV-3 infection of LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice (data not shown), and thus, it was not included in subsequent experiments.

Virologic and clinical laboratory studies were performed after DENV-3 infection in WT and LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice. Higher viral burdens at day 4 after DENV-3 infection were observed in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice only when enhancing antibodies to the anti-E MAb was administered (Fig. 4B to E; also data not shown). Hemoconcentration, lower platelet levels, enhanced liver enzymes (elevated AST and ALT), and renal injury (elevated BUN) were also observed in LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice after DENV-3 infection in the presence of enhancing antibodies (Fig. 4F to J), Thus, the LysM

**FIG 3** Viral burdens, cytokines, and vascular permeability following DENV-2 infection of LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice under ADE conditions. WT and LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice were infected with DENV-2 (10<sup>6</sup> FFU) via an intravenous route. Some of the LysM Cre<sup>+</sup> Ifnar<sup>-/-</sup> mice were pretreated with an isotype control MAb (CHK-152) or enhancing amounts of anti-prM and anti-E MAbs. (A to D) Levels of viral RNA in serum (A), kidney (B), spleen (C), and liver (D) samples harvested 4 days after infection were determined using qRT-PCR. Data are shown as log<sub>10</sub> DENV genome equivalents (GE) per 18S ribosomal RNA of tissue or per milliliter of serum from 11 to 16 mice per condition. The dotted line represents the limit of sensitivity of the assay. Asterisks indicate values that are statistically significant by the Mann-Whitney test compared to the values for isotype control MAb-treated mice. (E to H) Proinflammatory cytokine analysis. Cytokines IL-1β (E), IL-12p70 (F), IFN-γ (G), and TNF-α (H) were measured at day 4 after infection using a Bioplex instrument; the data reflect the results for 9 to 12 mice per group. Data are pooled from three to four independent experiments (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001 [Mann-Whitney test]). (I to L) Vascular permeability. Four days after infection, Evans blue dye was administered intravenously 20 min prior to sacrifice and tissue harvest. Levels of Evans blue (ng/mg tissue) in kidney (I), spleen (J), liver (K), and small intestine (L) were determined. Data are shown as ng of Evans blue per mg of tissue for 9 to 12 mice per group. Data are pooled from three to four independent experiments (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001 [Mann-Whitney test]).
Cre+ Ifnar−/− mouse model shows enhanced disease in the setting of ADE of two different DENV serotypes.

A bispecific tetravalent Fc-DART protects against DENV infection in LysM Cre+ Ifnar−/− mice. Previously, we generated an antibody-variable-region-based bispecific Ig-DART against DENV that targeted two distinct epitopes (49). That DART used WNV-E60, a cross-reactive neutralizing MAb that binds the fusion loop on DIII, and 4E11, a group-specific neutralizing MAb that binds the A-strand epitope on DIII. Our subsequent studies revealed that a second DIII fusion loop antibody, WNV-E119 (50), had superior inhibitory activity against other DENV serotypes (13; also data not shown). Accordingly, we generated a new bispecific tetravalent DART that contained the VH and VL regions of humanized WNV-E119 (hE119) and humanized 4E11 (h4E11) (Fig. 5A) (51, 52). This Fc-DART was engineered with the human IgG Fc constant regions (CH1, CH2, and CH3) containing a point mutation (N297Q) that prevents FcγR engagement and ADE (26). A nonbinding, bivalent DENV-4-type-specific IgG was developed as a negative control (Fig. 5A).

The initial studies confirmed the in vitro binding activity of N297Q h4E11 plus hWNV-E119A against recombinant E protein from prototype strains of all four DENV serotypes (data not shown). We next investigated the neutralization potential of the Fc-DART against the viruses we used for the in vivo studies and compared it to that of the parental h4E11 and hWNV-E119 MAb. The h4E11 MAb efficiently neutralized DENV-2 (50% effective concentration [EC50] of 20 ng/ml) and DENV-3 (EC50 of 29 ng/ml) (Fig. 5B and C). In comparison, the hWNV-E119 MAb neutralized DENV-2 (EC50 of 120 ng/ml) but not DENV-3 strain C0360/94. The h4E11–hWNV-E119A N297Q bispecific Fc-DART showed a neutralization profile that was consistent with the inhibitory activity of h4E11. To assess the utility of the LysM Cre+ Ifnar−/− mouse model of ADE and DENV pathogenesis, we performed protection studies using the bispecific N297Q Fc-DART. Initially, prophylaxis studies were performed against DENV-2. One 25-μg dose of the bispecific h4E11–hWNV-E119 N297Q Fc-DART administered one day prior to DENV-2 inoculation and enhancing treatment with anti-E plus anti-prM MAb completely protected LysM Cre+ Ifnar−/− mice against weight loss, viremia, thrombocytopenia, hemocoagulation, and liver injury (data not shown). Subsequently, LysM Cre+ Ifnar−/− mice were administered a single 25-μg dose of the bispecific N297Q Fc-DART 48 h after infection with DENV-2 or DENV-3 (Fig. 5D). The hE11–hWNV-E119 Fc-DART was active therapeutically, as judged by increased weight gain, reduced viral burden, and improved laboratory test values at 4 days after infection in the setting of ADE for either DENV-2 (Fig. 5E to J) and DENV-3 (Fig. 5K to P).

A RIG-I receptor agonist protects against severe DENV infection in LysM Cre+ Ifnar−/− but not Ifnar−/− mice. One of the limitations of using Ifnar−/− or AG129 mice is that the complete absence of IFNAR signaling does not permit the evaluation of anti-DENV therapies that act by modulating the host innate immune response. Recently, members of our group developed a 99-nucleotide, uridine-rich hairpin 5′-ppp RNA (termed M8) RIG-I agonist that can be delivered in vivo to stimulate protective antiviral responses against alphaviruses and orthomyxoviruses (53). We tested the utility of the LysM Cre+ Ifnar−/− model by administering M8 5′-ppp RNA in parallel to LysM Cre+ Ifnar−/− and Ifnar−/− mice prior to and after the addition of enhancing anti-prM and -E MAbS and DENV-2 (Fig. 6A). Protection, as judged by the absence of weight loss, was observed only in LysM Cre+ Ifnar−/− and not in Ifnar−/− mice (Fig. 6B). Associated with this clinical improvement, at day 4, we observed decreased viremia (Fig. 6C),

---

**TABLE 1** Cytokine levels in sera of DENV-2-infected WT and LysM Cre+ Ifnar−/− mice under ADE conditions

| Mouse treatment | WT mice, no MAb | LysM Cre+ Ifnar−/− mice, isotype MAb (P value vs WT) | LysM Cre+ Ifnar−/− mice, prM and E MAbs (P value vs WT, P value vs isotype MAb) |
|-----------------|-----------------|-----------------------------------------------------|------------------------------------------------------------------------------|
| IL-1α           | 5 ± 1           | 16 ± 2 (<0.0001)                                     | 20 ± 4 (0.0001; NS)                                                          |
| IL-1β           | 134 ± 23        | 262 ± 13 (<0.0001)                                  | 609 ± 45 (<0.0001; 0.0001)                                                   |
| IL-2            | 24 ± 1          | 42 ± 5 (0.01)                                       | 48 ± 6 (0.01)                                                                |
| IL-3            | 23 ± 1          | 62 ± 9 (0.01)                                       | 93 ± 3 (<0.0001; 0.01)                                                       |
| IL-4            | 16 ± 2          | 47 ± 5 (<0.0001)                                    | 50 ± 8 (0.001; NS)                                                           |
| IL-5            | 24 ± 4          | 89 ± 10 (<0.0001)                                  | 100 ± 11 (<0.0001; NS)                                                       |
| IL-6            | 35 ± 7          | 86 ± 17 (0.001)                                    | 88 ± 5 (<0.0001; NS)                                                         |
| IL-10           | 52 ± 6          | 62 ± 6 (NS)                                        | 80 ± 10 (NS; NS)                                                             |
| IL-12(p40)      | 59 ± 6          | 79 ± 12 (NS)                                        | 215 ± 49 (<0.0001; 0.0001)                                                   |
| IL-12(p70)      | 50 ± 6          | 71 ± 4 (0.01)                                       | 196 ± 22 (<0.0001; 0.0001)                                                   |
| IL-13           | 28 ± 3          | 44 ± 5 (0.04)                                       | 51 ± 7 (0.0026; NS)                                                          |
| IL-17           | 18 ± 1          | 40 ± 6 (0.02)                                       | 60 ± 4 (<0.0001; 0.007)                                                      |
| Eotaxin         | 592 ± 35        | 595 ± 101 (NS)                                      | 1,092 ± 165 (NS; 0.008)                                                      |
| G-CSF           | 110 ± 10        | 322 ± 73 (0.0004)                                   | 3,081 ± 745 (<0.0001; <0.0001)                                               |
| GM-CSF          | 64 ± 4          | 76 ± 15 (NS)                                        | 214 ± 7 (<0.0001; <0.0001)                                                   |
| IFN-γ           | 14 ± 1          | 17 ± 3 (NS)                                         | 36 ± 6 (0.001; 0.002)                                                        |
| KC              | 48 ± 7          | 111 ± 11 (<0.0001)                                  | 1,171 ± 307 (<0.0001; <0.0001)                                               |
| MCP-1           | 219 ± 34        | 712 ± 92 (<0.0001)                                  | 1,973 ± 349 (<0.0001; <0.0001)                                               |
| MIP-1α          | 5 ± 0           | 8 ± 1 (NS)                                          | 25 ± 1 (<0.0001; <0.0001)                                                     |
| MIP-1β          | 41 ± 9          | 74 ± 6 (0.0014)                                     | 135 ± 7 (<0.0001; <0.0001)                                                   |
| RANTES          | 7 ± 1           | 20 ± 8 (<0.0001)                                    | 323 ± 113 (<0.0001; <0.0001)                                                 |
| TNF-α           | 480 ± 81        | 609 ± 50 (NS)                                       | 1,815 ± 221 (<0.0001; <0.0001)                                               |

* Mice were pretreated with the indicated MAb(s) (none, isotype control anti-CHK-152, or enhancing anti-prM and anti-E MAbS) one day prior to infection with DENV-2. On day 4 after infection, sera were harvested and processed for cytokines and chemokines as described in Materials and Methods. Data from 9 to 12 mice per group in three or four independent experiments were pooled. Statistical significance was assessed using the Mann-Whitney test. NS, not significant.
DENV-3 infection in LysM Cre−/−Ifnar−/− mice was administered 2 days after infection in the setting of ADE (Fig. 7A). Therapeutic administration of M8 5′-ppp RNA after infection with DENV-2 or DENV-3 resulted in improved weight gain in the M8-treated group, with a significant difference in weight at 4 days postinfection compared to the results for the control (Fig. 7B and G). Concurrently, there was a reduction in viremia (Fig. 7C and H), a normalization of platelet levels (Fig. 7D and I), and an improvement in liver function tests (Fig. 7E, F, J, and K) associated with M8 treatment. These results suggest that RIG-I activation is a potential therapeutic target during the course of DENV infection.

DISCUSSION

DENV continues to emerge globally, with an estimated 390 million infections per year (54). Infection by the four distinct serotypes can cause several clinical syndromes, ranging from the debilitating DF to life-threatening shock syndrome. Severe DENV disease most often is associated with a second infection with a heterologous DENV serotype, due to the presence of preexisting and nonneutralizing, cross-reactive antibodies and/or T cells. Although live-attenuated tetravalent prophylactic vaccines are in advanced clinical evaluation (55–58), there is still a need for therapeutics that can be utilized in DENV-infected individuals. Preclinical testing has been hampered by the lack of small animal models that support DENV replication and pathogenesis. Most studies have used highly immunocompromised mice lacking intact type I and type II IFN signaling pathways (59). Here, using LysM Cre+ Ifnar−/− mice that delete Ifnar expression only on a subset of target myeloid cells, we established a more immunocompetent model of DENV infection using enhancing antibodies as was done in our previous studies. This model enables the use of Fc-DART and a RIG-I receptor immunomodulatory agonist.

A prior study showed that LysM Cre+ Ifnar−/− mice were vulnerable to DENV-2 infection (40). Rather than try to augment DENV disease using enhancing antibodies as was done in our study, this group showed that an Ifnar deficiency on CD11c+ dendritic cells or LysM+ macrophages resulted in complete lethality.
after infection with a 10-fold-higher dose of DENV-2. The mice lacking Ifnar expression only on myeloid cell subsets developed a robust DENV-specific CD8+ T cell response, compared to a weak response in Ifnar−/− mice, and sustained a protective immune response to a candidate subunit vaccine. Our experiments confirm and extend these findings. First, in the direct DENV-2 infection model in LysM Cre conditional Ifnar f/f mice, we observed increased viral infection, elevated levels of cytokines, and altered laboratory parameters without significant mortality, which is characteristic of primary DENV infection in humans. These results confirm that protection of mice from DENV infection depends on type I IFN signaling in LysM-expressing myeloid cells. Second, we showed greater DENV infection and disease in LysM Cre conditional Ifnar f/f mice when preexisting enhancing anti-prM and anti-E antibodies were present. This led to the development of a vascular leakage syndrome, which parallels that seen in severe DENV (60). Third, we extended our findings in LysM Cre conditional Ifnar f/f mice to a second DENV serotype, using a nonadapted DENV-3 isolate.

A criticism of existing Ifnar-deficient mouse models of DENV is that the type I IFN receptor signaling pathway is required for optimal antigen-specific T and B cell priming, expansion, and memory formation (40). The LysM Cre conditional Ifnar f/f mouse model overcomes these limitations and more closely recapitulates several aspects of human disease. The deletion of Ifnar expression on LysM mouse myeloid cells overcomes the species immune antagonism issues and enables higher levels of DENV infection and inflammatory responses in myeloid cells, which are the natural cellular targets in human disease (41). Although LysM Cre conditional Ifnar f/f mice supported increased DENV replication, showed signs of illness, and developed thrombocytopenia during primary infection, they did not develop hemocoagulation, vascular leakage, or lethality when virus alone was administered. In comparison, when enhancing antibodies against prM and E were provided, the viral burden was greater, and this was associated with more severe disease, including death, as is seen in the most severe cases of dengue in humans.
Another limitation of DENV infection experiments in Ifnar−/− or AG129 mice is that most agonists that modulate innate immune responses cannot be evaluated. There is increasing interest in the development of molecules that can stimulate IRF3 and/or type I IFN responses as means of controlling virus infection. Such agents may be important particularly in the context of DENV, which can inhibit IRF3 and IFN induction by virtue of its ability to antagonize STING-dependent responses (37, 38). However, such agents would not induce robust antiviral responses in mice lacking type I IFN responses in all cells. Indeed, 5′-ppp RNA moieties that activate RIG-I had no therapeutic effect against DENV in Ifnar−/− mice. In comparison, administration of the M8 5′-ppp RNA pathogen-associated molecular pattern protected LysM CreIfnarf/f mice from severe DENV disease. These experiments establish the utility of the conditional LysM Cre Ifnarf/f mouse model for testing possible novel immunomodulatory therapies against DENV.

We previously generated a bispecific tetravalent Ig-DART (E60 and 4E11) and showed protective activity against DENV in AG129 mice (49). In the current study, we used a different cross-reactive DII fusion loop MAb (E119) and a sequence-optimized version of a group-specific MAb (4E11) (52) to create a new bispecific tetravalent Fc-DART with an N297Q modified Fc region that cannot promote ADE in vitro or in vivo. This Fc-DART showed marked protective activity against DENV-2 and DENV-3 in LysM CreIfnarf/f mice and prevented clinical disease and laboratory parameter abnormalities. These experiments confirm the utility of Fc-modified-antibody-based therapeutics against DENV (24, 26).

In summary, we established LysM CreIfnarf/f mice as a more immunocompetent model of antibody-enhanced DENV infection in vivo. We demonstrated the utility of this model by administering antibody- or innate immune-based therapeutic agents against two different DENV serotypes, including a non-mouse-adapted DENV-3 strain. Future studies are planned to evaluate the pathogenesis of the remaining two DENV serotypes (DENV-1 and DENV-4) and assess whether disease occurs in LysM CreIfnarf/f mice using circulating, contemporary, and other non-mouse-adapted isolates.

MATERIALS AND METHODS

Ethics statement. This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381-01). Dissections and injections were performed under anesthesia that was induced with ketamine hydrochloride and xylazine.

Viruses and cells. DENV-2 strain D2S20 is a mouse-adapted strain and has been described previously (33). In the current study, we used a different cross-reactive DII fusion loop MAb (E119) and a sequence-optimized version of a group-specific MAb (4E11) (52) to create a new bispecific tetravalent Fc-DART with an N297Q modified Fc region that cannot promote ADE in vitro or in vivo. This Fc-DART showed marked protective activity against DENV-2 and DENV-3 in LysM CreIfnarf/f mice and prevented clinical disease and laboratory parameter abnormalities. These experiments confirm the utility of Fc-modified-antibody-based therapeutics against DENV (24, 26).
mouse-adapted DENV-3 Thai human isolate (strain C0360/94) (27). All viruses were passaged in C6/36 Aedes albopictus cells and ultracentrifuged (30,000 RPM for 90 min in SW32 rotor [110,500 g]) through a 25% glycerol cushion. Pelleted virus was resuspended in 10 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM EDTA, and stored at −80°C. The titers of virus stocks were determined by a focus-forming assay on Vero cells (49).

Mice. WT C57BL/6 mice were purchased commercially (Jackson Laboratories). Ifnar−/− mice (61) were backcrossed for 10 generations onto the C57BL/6 background. LysM Cre Ifnarfl/fl mice were obtained from R. Schreiber (St. Louis, MO) and U. Kalinke (Hannover, Germany). The Ifnarfl/fl (62) and LysM Cre Ifnarfl/fl mice were backcrossed using speed congenic analysis to 99% C57BL/6 as judged by microsatellite analysis. Mice (4 to 5 weeks old) were inoculated intravenously with DENV-2 (D2S20) or DENV-3 (C0360/94).

Analysis of Ifnar expression. Blood was obtained by intracardiac heart puncture, and spleens were recovered. Live cells were stained with MAb specific for CD11c, CD3, class II major histocompatibility complex (MHC), CD11b, B220, and Ifnar (BioLegend) to define cell types and determine Ifnar expression. All samples were processed on an LSRII or Fortessa flow cytometer (BD Biosciences). The resulting data were analyzed using FlowJo (Treestar).

Fc-DART generation. To humanize WNV-E119 antibody (50), the complementarity-determining regions (CDRs) from VH and VL were grafted onto the most homologous human germline antibody framework sequences, VH3-48/VH3-23 and Vκ-A30/Vκ-L15, respectively. For humanization of the 4E11 antibody (52), the CDRs from VH and VL were grafted onto the human germline antibody framework sequences VH1-46 and Vκ-B3, respectively. Necessary framework back mutations were engineered to rescue the antibody binding affinity. The Fc-DART was produced from plasmids that coexpressed two polypeptide chains: chain 1, with the humanized VL domain of WNV-E119 linked to the humanized VH domain of 4E11, followed by a K coil sequence, and chain 2, with the humanized VL of 4E11 linked to the humanized VH of WNV-E119, followed by an E coil sequence and the CH2 and CH3 of the human constant region, containing an N297Q point mutation that abolishes C1q and FcR interactions (63). The oppositely charged E coil and K coil promote the heterodimerization of chain 1 and chain 2, and this assembly is stabilized further by an interchain disulfide bond within the E-coil/K-coil domain. The Fc-DART was expressed in CHO-S cells and purified from supernatants by serial protein A affinity and Superdex 200 size exclusion chromatography to generate purified recombinant material.

Animal treatments. (i) ADE studies. To induce ADE, mice were treated via the intravenous route with the flavivirus cross-reactive antibody 4G2 (64) (10 μg/mouse) for DENV-3 or with the combination of dengue complex-specific anti-prM antibody 2H2 (64) and 4G2 (15 μg each MAb per mouse) for DENV-2 one day prior to infection.

(ii) Fc-DART therapy. Mice were treated via an intraperitoneal route with 25 μg/mouse of h4E11–WNV-hE119 N297Q Fc-DART or negative-control recombinant (type-specific DENV-4 hE88 N297Q [13]) IgG either one day prior to infection or at 48 h after infection.

(iii) RIG-I agonist treatment. Mice were treated with a single dose (5 μg/mouse) of a 99-nucleotide, uridine-rich hairpin 5’-ppp RNA termed M8 (53, 65) or a synthetic RNA control lacking 5’-ppp control

FIG 7 Postexposure therapy with a RIG-I receptor agonist controls DENV-2 and DENV-3 infection and disease in LysM Cre+ Ifnar−/− mice. (A) Scheme of treatment and infection. LysM Cre+ Ifnar−/− mice were injected with 15 μg of anti-prM MAb (DENV-2 only) and anti-E MAb (DENV-2 and DENV-3) and infected one day later with 106 FFU of DENV-2 D2S20 (B to F) or 107 FFU of DENV-3 C0360/94 (G to K). Two days after DENV infection, mice were treated with 5 μg of 5’-ppp M8 RNA or control RNA. Weight loss was monitored for 4 days (B and G). Laboratory parameters, including viremia (C and H), platelet counts (D and I), and levels of liver enzymes AST (E and J) and ALT (F and K) in serum were monitored as in described in the legend to Fig. 5. Two independent experiments were performed, with 3 mice per group per experiment. Statistically significant differences between individual groups were determined by using the Mann-Whitney test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
combined with jetPEI transfection reagent (Polyplus) via intravenous injection before and after infection.

**qRT-PCR analysis of viral burden.** Fluorogenic quantitative RT-PCR (qRT-PCR) was used to measure viral genome copy number. Total RNA from organs or serum of infected animals was isolated using the Qiagen RNeasy kit or the Qiagen viral RNA isolation kit. DENV viral RNA was determined using the pan-DENV primer probe set (66), which recognizes a conserved sequence in the 3′ untranslated region of all DENV serotypes. Viral copy number was determined using a defined positive single-stranded RNA generated in vitro using T7 polymerase containing the DENV target sequences.

**Neutralization assay.** Focus-forming reduction neutralization assays (FRNTs) were performed as described previously (49) to determine the 50% inhibitory concentrations of Mabs and Fc-DARTs against the virus isolates used to infect mice. Infected foci were enumerated by counting using a CTL-Immunosport S6 (Cellular Technology Limited).

**Clinical hematology and chemistry analysis.** At specified times after DENV infection of mice, blood was collected by intracardiac heart puncture. Blood for clinical hematology was analyzed into EDTA-coated tubes (Becton Dickinson), and analyzed using a ProCyte DX machine (IDEXX). Serum was collected for clinical chemistry analysis of alanine transaminase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) using the ProCyte DX machine.

**Cytokine and chemokine measurements.** The BioPlex Pro assay (Bio-Rad) was performed according to the manufacturer’s protocol on serum isolated at day 4 postinfection. The cytokine screen included IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, Eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, KC, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, RANTES (CCL5), and tumor necrosis factor alpha (TNF-α).

**Vascular permeability analysis.** Two hundred microliters of sterile filtered Evans blue solution (0.5% [wt/vol]) in phosphate-buffered saline (PBS) was injected intravenously. After 20 min, mice were sacrificed and perfused with 40 ml of PBS. Livers, spleens, small intestines, and kidneys were collected into tubes containing formaldehyde (Fisher Scientific), homogenized, weighed, and incubated overnight at 25°C. The following day, samples were centrifuged at 14,000 × g and 100 µl of supernatant was quantified at 610 nm against a standard curve generated by serial dilutions of a stock Evans blue solution.

**Statistical analysis.** All data were analyzed using Prism software (GraphPad, San Diego, CA). Kaplan-Meier survival curves were analyzed by the log rank test. Differences in results for viral burden, clinical chemistry and hematology, cytokine levels, and Evans blue staining were analyzed by the Mann-Whitney test.

**ACKNOWLEDGMENTS**

We gratefully acknowledge Ulrich Kalinke and Robert Schreiber for providing the Ifnar-/- and LysM Cre+ Ifnar-/- mice and William Tang and William Eddy for technical assistance in some of the experiments.

This work was supported by the Burroughs Wellcome Fund (M.S.D.), NIH grants R01 AI077955 (M.S.D.), R01 AI108661 (J.H.), U54 AI075171 (the Southeastern Regional Center of Excellence for Emerging Infectious and Biodefense), and R01 AI108563 (S.S.). V.V.S. was supported by a T32 postdoctoral fellowship (NIAID AI 7536-13).

**REFERENCES**

1. Halstead SB, Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42:311–328.

2. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38:411–419.

3. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, Lien LB, Quy NT, Hieu NT, Hieu LT, Hien TT, Hung NT, Farrar J, Simmons CP. 2008. Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198:516–524. http://dx.doi.org/10.1086/590117.

4. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanism of an antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229–238. http://dx.doi.org/10.1016/j.chom.2008.08.004.

5. Diamond MS, Pierson TC. 2015. Molecular insight into dengue virus pathogenesis and its implications for disease control. Cell 162(3): 488–492. http://dx.doi.org/10.1016/j.cell.2015.07.005.

6. Dejnirattisai W, Jummasıngon A, Omsirimakul N, Fulton P, Vasanthawathana S, Limpiwut P, Putthibun G, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malamat P, Mongkolpapaya J, Screaton G. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745–748. http://dx.doi.org/10.1126/science.1158151.

7. Beltramelli M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukulopetty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanza-vacccia A, Sallusto F. 2010. The human immune response to dengue infection is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271–283. http://dx.doi.org/10.1016/j.chom.2010.08.007.

8. De Alwis R, Beltramelli M, Messer WB, Sukulopetty S, Wahala WM, Kraus A, Obrívez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanza-vacccia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the anti-dengue antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e11188. http://dx.doi.org/10.1371/journal.pntd.0001188.

9. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE. 2014. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 88:12233–12241. http://dx.doi.org/10.1128/JVI.01847-14.

10. Brien JD, Alwis SK, Sukulopetty S, O’Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84:10630–10643. http://dx.doi.org/10.1128/JVI.01190-10.

11. Sukulopetty S, Alwis SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9277–9239. http://dx.doi.org/10.1128/JVI.01087-10.

12. Srishtila B, Brien JD, Sukulopetty S, Alwis SK, Edeling MA, Kim T, O’Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous types of dengue virus type 1. PLoS Pathog 6:e1000823. http://dx.doi.org/10.1371/journal.ppat.1000823.

13. Sukulopetty S, Brien JD, Alwis SK, Srishtila B, Swayne S, Kahle K, Doranj BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. 2013. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 87:8826–8842. http://dx.doi.org/10.1128/JVI.01314-13.

14. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349–360. http://dx.doi.org/10.1016/j.virology.2007.05.042.

15. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828–8837. http://dx.doi.org/10.1128/JVI.01060-08.

16. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6:e1000821. http://dx.doi.org/10.1371/journal.ppat.1000821.

17. de Alwis R, Smith SA, Obrívez NP, Messer WB, Huyhn JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439–7444. http://dx.doi.org/10.1073/pnas.1200566109.

18. Teoh EP, Kukkarao P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuuchenko VA, Le YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi
Rouvinski et al.

EMBO Mol Med 6:358–371. http://dx.doi.org/10.1002/emmm.201303404.

Fibriansah et al.

Nature 439:520–524. http://dx.doi.org/10.1038/nature04402.

Milligan et al.

PLoS Pathog 8:e1002934. http://dx.doi.org/10.1371/journal.ppat.1002934.

Ashour et al.

PLoS Pathog 8:e1002780. http://dx.doi.org/10.1371/journal.ppat.1002780.

Pinto et al.

PLoS Pathog 10:e1004086. http://dx.doi.org/10.1371/journal.ppat.1004086.

Züst et al.

PLoS Pathog 10:e1003806. http://dx.doi.org/10.1371/journal.ppat.1003806.

Borden et al.

Nat Rev Immunol 15:231–242. http://dx.doi.org/10.1038/nri3806.

Rathakrishnan et al.

Arch Virol 158:1445–1459. http://dx.doi.org/10.1007/s00705-013-1645-0.

Bahita SI, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Kaye JL, Mehlhop E, Johnson S, Sallusto F, Cerny D, Heinrich J, Ransohoff RM, Foster GR, Stark GR. 2008. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J Virol 82:7276–7285. http://dx.doi.org/10.1128/JVI.00827-13.

Durbin AP, Vargas MJ, Wanonek J, Hammond SN, Gordon A, Rocha C, Balmaseda A, Harris E. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429–435. http://dx.doi.org/10.1016/j.virol.2008.03.028.

Pinto et al.

PLoS Pathog 10:e1005422. http://dx.doi.org/10.1371/journal.ppat.1005422.

Rathakrishnan et al.

PLoS One 5:6537–6543. http://dx.doi.org/10.1371/journal.pone.0054220.

Borden EG, Sen GC, Uze G, Silverman RH, Ransohoff RF, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975–990. http://dx.doi.org/10.1038/nrd2242.

Prchal et al.

PLoS Pathog 9:e1003312. http://dx.doi.org/10.1371/journal.ppat.1003312.

Rathakrishnan et al.

PLoS ONE 9:e92021. http://dx.doi.org/10.1371/journal.pone.0092021.

Rathakrishnan et al.

PLoS Pathog 9:e1003312. http://dx.doi.org/10.1371/journal.ppat.1003312.
dual-affinity retargeting antibodies against dengue virus. J Virol 87: 7747–7753. http://dx.doi.org/10.1128/JVI.00327-13.
50. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshesky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J Virol 80:12149–12159. http://dx.doi.org/10.1128/JVI.01732-06.
51. Thuiller P, Demangel C, Bedouelle H, Mégret F, Jouan A, Deubel V, Mazié JC, Lafaye P. 2001. Mapping of the dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82:1885–1892.
52. Cockburn JJ, Navarro Sanchez ME, Freites N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenaza Seisdedos F, Bedouelle H, Roy FA. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303–314. http://dx.doi.org/10.1016/j.str.2012.01.001.
53. Chiang C, Beljanski V, Yin K, Olagnier B, Ben Yehdri F, Steel C, Goulet ML, DeFilippis VR, Streblo DN, Haddad EK, Trautmann L, Ross T, Lin R, Hiscott J. 2015. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J Virol 89:8011–8025. http://dx.doi.org/10.1128/JVI.00845-15.
54. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JH, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504–507. http://dx.doi.org/10.1038/nature12060.
55. Osorio JE, Velez ID, Thomson C, Lopez J, Jimenez A, Haller AA, Silengo S, Scott J, Borroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT. 2014. Safety and immunogenicity of a recombinant live attenuated dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomized, placebo-controlled, phase 1 study. Lancet Infect Dis 14: 830–838. http://dx.doi.org/10.1016/S1473-3099(14)00811-4.
56. Capeding MR, Tan NH, Hadinegoro SR, Ismail HI, Chotpitaya-sunondh T, Chua MN, Luong QC, Ruzmil K, Wirawan DN, Nallusamy R, Pitasittithum P, Thiyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Fraco C, Boaz M, Wartel TA, Torneporph NG, Saville M, Bouckenhooge A. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 1358–1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
57. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reyesales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langvin E, Boaz M, Torneporph N, Saville M, Noriega F. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113–123. http://dx.doi.org/10.1126/NEJMoa1411057.
58. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Sub-barao K, Whitehead SS. 2015. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 212:702–710. http://dx.doi.org/10.1093/infdis/jiv082.
59. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80:10208–10217. http://dx.doi.org/10.1128/JVI.00062-06.
60. Guzman MG, Harris E. 2015. Dengue. Lancet 385:453–465. http://dx.doi.org/10.1016/S0140-6736(14)60572-9.
61. Müller U, Steinhoﬀ U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918–1921. http://dx.doi.org/10.1126/science.8009221.
62. Le Bon A, Durand V, Kamphuis E, Thompson C, Bullfone-Paus S, Rossmann C, Kalinke U, Tough DF. 2006. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176:4682–4689. http://dx.doi.org/10.4049/jimmunol.176.8.4682.
63. Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595–2601.
64. Brandt WE, McCown JM, Gentry MK, Russell PK. 1982. Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect Immun 36:1036–1041.
65. Goulet ML, Olagnier D, Xu Z, Par S, Belgnauoi SM, Lafferty EL, Janelle V, Arguello M, Paquet M, Ghein K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J. 2013. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 9:e1003298. http://dx.doi.org/10.1371/journal.ppat.1003298.
66. Gurukumar KR, Priyadarshini D, Patil JA, Bhagat A, Singh A, Shah PS, Cecilia D. 2009. Development of real time PCR for detection and quantitation of dengue viruses. Virol J 6:10. http://dx.doi.org/10.1186/1743-422X-6-10.